The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.

At 8 weeks, the aliskiren group had a slightly lower eGFR than the placebo group (53.6±29.2 vs 58.0±35.6 ml/min/1.73 m 2 , p = 0.059), but the result did not reach statistical significance.

also in 111,027 other papers